Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 8/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.30 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.30 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.30 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496156 | 0.86 | GHSR (0.34) | CA2MMP3AGTR1CTSKLTB4R2 | |
| SCHEMBL6480737 | 0.86 | LTB4R2 (0.35) | CA2MMP3AGTR1CTSKLTB4R2 | |
| SCHEMBL6489933 | 0.83 | GHSR (0.37) | — | |
| SCHEMBL6488832 | 0.81 | MMP9 (0.43) | — | |
| SCHEMBL6483759 | 0.80 | SLC6A2 (0.33) | AGTR1LTB4R2 | |
| SCHEMBL6483716 | 0.75 | NPY1R (0.38) | MMP3AGTR1CTSKLTB4R2AGTR2 | |
| SCHEMBL6482436 | 0.75 | HDAC1 (0.40) | — | |
| SCHEMBL6491914 | 0.73 | F2 (0.45) | CA2 | |
| SCHEMBL6480782 | 0.71 | GHSR (0.46) | — | |
| SCHEMBL6481968 | 0.71 | HDAC8 (0.44) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261332-A1 | Sulfonamides and uses thereof | ELIXIR PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261332-A1 | Sulfonamides and uses thereof | GLS2, STS, ABAT | CA2 3211/4885MMP3 1747/4885AGTR1 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.